When was CereVasc founded?

CereVasc was founded in 2015 and raised its 1st funding round 5 years after it was founded.

Where is CereVasc located?

CereVasc is headquartered in Auburndale, United States.

Is CereVasc a funded company?

CereVasc is a funded company, having raised a total of $199M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on May 22, 2020.

When was the latest funding round of CereVasc?

CereVasc's latest funding was a $***** Series C round on Jun 04, 2026, with participation from 5 investors.

Where does CereVasc rank among its competitors?

CereVasc ranks 1st amongst 12 active competitors, of which 6 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was CereVasc, which secured $85M in Jun, 2026.

Who are the top competitors of CereVasc?

CereVasc's top competitors include IRRAS, Longeviti and Rhovica. Among them, CereVasc secured the most recent funding round in June, 2026.

CereVasc - 2026 Company Profile, Team, Funding & Competitors

CereVasc is a series C company based in Auburndale (United States), founded in 2015 by Patrick Sullivan, Carl Heilman and Adel Malek. It operates as a Device for the treatment of patients with communicating hydrocephalus. CereVasc has raised $199M in funding from investors like Bain Capital, ATON Partners and Xontogeny. The company has 12 active competitors, including 6 funded and 2 that have exited. Its top competitors include companies like IRRAS, Longeviti and Rhovica.

Company Details

CereVasc is developing eShunt, a device for the treatment of patients with communicating hydrocephalus (a neurological condition affecting both children and adults). The company is developing a non-invasive solution including a cerebrospinal fluid shunt and catheter-based delivery system.

Website: cerevasc.com
Email ID: *****@cerevasc.com

Key Metrics

Founded Year

2015

Location

Auburndale, United States

Stage

Series C

Total Funding

$199M in 3 rounds

Latest Funding Round

Series C, Jun 04, 2026, $*****

Investors

Bain Capital & 7 more

Ranked

1^st among 12 active competitors

Similar Companies

IRRAS & 13 more

View CereVasc's full profile

CereVasc has raised a total funding of $199M over 3 rounds. Its first funding round was on May 22, 2020. Its latest funding round was a Series C round on Jun 04, 2026 for $*****. 5 investors participated in its latest round. CereVasc has 8 institutional investors.

Here is the list of recent funding rounds of CereVasc:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 04, 2026	7207352	Series C	3792344	6460885	5061415	4448463
May 13, 2024	5369984	Series B	5840663	5911808	1125766	Xontogeny
May 22, 2020	2852610	Series A	2176848	3544791	ATON Partners & 1 more	3465380

Access funding benchmarks and valuations. Sign up today!

View details of CereVasc's funding rounds and investors

The founders of CereVasc are Patrick Sullivan, Carl Heilman and Adel Malek.

Here are the details of CereVasc's key team members:

Patrick Sullivan: Co-Founder of CereVasc and founder of 1 other company.
Carl Heilman: Co-Founder of CereVasc.
Adel Malek: Co-Founder of CereVasc.

View details of CereVasc's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of CereVasc include IRRAS, Longeviti and Rhovica. Here is the list of Top 10 competitors of CereVasc, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	CereVasc 2015, Auburndale (United States), Series C	Device for the treatment of patients with communicating hydrocephalus	$199M	Bain Capital Life Sciences, Medtronic & 6 others	62/100
2nd	IRRAS 2012, Stockholm (Sweden), Acquired	Provider of devices for fluid control and management after surgery	$11.3M	Serendipity Innovations, Invest Stockholm ... & 2 others	54/100
3rd	Longeviti 2014, Hunt Valley (United States), Series B	Developer of implantable neurosurgical devices	$18.2M	TEDCO, GSP Capital	53/100
4th	Rhovica 2021, Bern (Switzerland), Seed	Developer of an external ventricular drain to decrease intracranial pressure	$2.92M	M2care, Venture Kick & 2 others	40/100
5th	Aqueduct Critical Care 2013, Bothell (United States), Series A	Novel products to manage Cerebral Spinal Fluid (CSF) pressure	$10.3M	SeaChange Fund, Mighty Capital & 5 others	39/100
6th	Tissuemed 1985, Leeds (United Kingdom), Acqui-Hired	Bioadhesive films to prevent body fluid and air leakage during surgery	$12.7M	Saints Capital, Shackleton Ventures & 5 others	39/100
7th	CranioSense 2015, Waltham (United States), Seed	Innovating non-invasive intracranial pressure measurement technology for better brain health	$20K	Techstars, NINDS & 1 others	30/100
8th	Aqueduct Neurosciences 2010, Seattle (United States), Deadpooled	Implantable shunt to treat hydrocephalus	$8.79M	HEDA Ventures, The Perkins Fund & 2 others	28/100
9th	Spiegelberg 1986, Hamburg (Germany), Acquired	Intracranial pressure(ICP) measuring devices, external ventricular drainage (EVD), shunts and Surgical Instruments.	-	-	26/100
10th	NeuroDx 2008, Bensalem (United States), Funding Raised	Detects CSF flow in shunts using non-invasive thermal dilution	-	Ben Franklin Technology Partners, MentorTech Ventures ... & 3 others	25/100